HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging [corrected].

AbstractOBJECTIVES:
The aim of this study was to investigate the role of reduced lecithin: cholesterol acyltransferase (LCAT) function on atherogenesis using 3.0-T carotid magnetic resonance imaging (MRI) and B-mode ultrasound.
BACKGROUND:
The role of low high-density lipoprotein cholesterol as a causal factor in atherogenesis has recently been questioned. LCAT plays a key role in high-density lipoprotein cholesterol metabolism.
METHODS:
Carotid 3.0-T MRI and B-mode ultrasound measurements were performed in 40 carriers of LCAT gene mutations and 40 controls, matched for age. Patients with cardiovascular disease were excluded.
RESULTS:
Carriers had 31% lower LCAT activity levels and 38% decreased high-density lipoprotein cholesterol levels (both p < 0.001 vs. controls). Carriers presented with a 10% higher normalized wall index (0.34 ± 0.07 vs. 0.31 ± 0.04, p = 0.002), a 22% higher mean wall area (17.3 ± 8.5 mm(2) vs. 14.2 ± 4.1 mm(2), p = 0.01), and a 22% higher total wall volume (1,039 ± 508 mm(3) vs. 851 ± 247 mm(3), p = 0.01 vs. controls) as measured by MRI. The prevalence (20 vs. 5, p = 0.002) and the total volume (102 mm(3) vs. 3 mm(3)) of atherosclerotic plaque components on MRI relating to lipid-rich tissue or calcification were also higher in carriers than in controls. All differences retained significance after adjustment for age, sex, blood pressure, low-density lipoprotein cholesterol, body mass index, smoking, and family history of cardiovascular disease. Common carotid intima-media thickness measured with ultrasound was increased in carriers by 12.5% (0.72 ± 0.33 mm vs. 0.64 ± 0.15 mm, p = 0.14).
CONCLUSIONS:
Carriers of LCAT gene mutations exhibit increased carotid atherosclerosis, indicating an increased risk of cardiovascular disease. The present findings imply that increasing LCAT activity may be an attractive target in cardiovascular prevention strategies.
AuthorsRaphaël Duivenvoorden, Adriaan G Holleboom, Bas van den Bogaard, Aart J Nederveen, Eric de Groot, Barbara A Hutten, Alinda W Schimmel, G Kees Hovingh, John J P Kastelein, Jan Albert Kuivenhoven, Erik S G Stroes
JournalJournal of the American College of Cardiology (J Am Coll Cardiol) Vol. 58 Issue 24 Pg. 2481-7 (Dec 06 2011) ISSN: 1558-3597 [Electronic] United States
PMID22133847 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Cholesterol, HDL
  • Phosphatidylcholine-Sterol O-Acyltransferase
Topics
  • Adult
  • Atherosclerosis (genetics, physiopathology)
  • Carotid Arteries (diagnostic imaging, pathology)
  • Carotid Artery Diseases (diagnosis, diagnostic imaging, genetics, metabolism)
  • Carotid Intima-Media Thickness
  • Cholesterol, HDL (metabolism)
  • Female
  • Heterozygote
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Mutation
  • Phosphatidylcholine-Sterol O-Acyltransferase (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: